RHEUMATOLOGY

Review

Takayasu arteritis: advanced understanding is leading to new horizons

Enrico Tombetti[1,2] and Justin C. Mason[2]

Abstract

Although outcomes in Takayasu arteritis (TAK) are improving, diagnosis is typically delayed and significant arterial injury accrues. While wider use of non-invasive imaging is impacting this, the onus remains with clinicians to consider a diagnosis of TAK earlier. Meanwhile, morbidity and mortality in TAK remains increased. Herein we review the current situation, outline recent advances and summarize remaining challenges. Understanding of disease pathogenesis remains poor. However, recent genetic data and identification of pathogenic cytokines may facilitate the search for biomarkers capable of distinguishing active and inactive disease, inflammatory and non-inflammatory arterial remodelling. Imaging is critical for TAK, and each modality has important strengths and limitations. Dependence upon CS therapy remains too high. However, the impact of combination immunosuppressive therapy is now recognized, biologic therapies are increasingly available and new agents offer promise. Multicentre clinical trials are now required, and these will depend upon development of defined clinical and imaging end-points.

Key words: large vessel vasculitis, Takayasu arteritis, biomarkers, imaging, biologic therapy

---

Rheumatology key messages

- Early diagnosis and effective combination therapy including biologics can improve outcomes in Takayasu arteritis.
- Novel biomarkers are required for distinguishing inflammatory and non-inflammatory remodelling in Takayasu arteritis.
- Defined clinical and imaging end-points are required in order to optimize future clinical trials in Takayasu arteritis.

Introduction

Takayasu arteritis (TAK) is a rare, idiopathic systemic inflammatory disease affecting large arteries, including the aorta, its major branches and the pulmonary arteries. TAK is predominantly a disease of the young adult, typically presenting in the second and third decades of life [1], and may also affect children [2]. Arterial inflammation is the core feature of the disease, variably associated with a systemic acute-phase response. Inflammatory lesions are characterized by arterial wall thickening and frequently result in remodelling of the arterial lumen following myofibroblast proliferation. In most series, 90% of patients suffer arterial stenoses, and up to 25% aneurysmal disease (Fig. 1). Six predominant patterns defined by angiography and expanded further by non-invasive imaging have been described [3, 4].

Recent success in the management of other vasculitides and the wider application of non-invasive imaging to large vessel vasculitis (LVV) has led to renewed interest and awareness of TAK. The effectiveness of ANCA-associated vasculitis therapy exposes the limitations in the management of TAK and the relative lack of progress. Significant morbidity persists in TAK. Daily activities are compromised in 74%, while mortality remains up to 5% at 10 years [1] and as high as 27% in the most severely affected [5]. Outcomes are closely aligned to the degree of arterial injury. Although longitudinal data suggests that combination immunosuppression is beginning to impact patient outcomes [6], important shortcomings remain.

This review will address recent areas of improvement in the understanding and management of TAK. These include non-invasive imaging modalities, emerging genetic data, wider use of immunosuppressive drugs early in the

[1]Department of Immunology, Transplantation and Infections Disease, Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milan, Italy and [2]Vascular Sciences and Rheumatology, Imperial Centre for Translational and Experimental Medicine, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK

Submitted 19 October 2017; revised version accepted 1 January 2018

Correspondence to: Justin C. Mason, Vascular Sciences and Rheumatology, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.
E-mail: justin.mason@imperial.ac.uk

Fɪɢ. 1 Impact of arterial disease in TAK

(**A**) Characteristic severe left subclavian artery stenosis (arrow) with associated collaterals (asterisk). (**B**) Large ascending aortic aneurysm (arrow) with cuffing of the aorta by inflammatory tissue seen around the descending aorta (arrowhead). (**C**) ^{18}F-FDG-CT-PET scan showing intense homogenous uptake in the arch of the aorta, consistent with aortitis (arrow). (**D**) Colour Doppler ultrasound study illustrating concentric homogenous thickening of the wall of the common carotid artery. TAK: Takayasu arteritis; ^{18}F-FDG-CT-PET: 2-[18F]-fluoro-2-deoxy-D-glucose-CT-PET.

disease course and increasing access to biologic therapies. Likewise, persisting limitations, including delayed diagnosis, a paucity of clinical trial data and an unacceptable burden of arterial injury and excessive drug-induced toxicity, will be discussed. Current understanding of disease pathogenesis and the need for novel biomarkers, improved activity and damage indices will also be addressed. Finally, prospects for the future, including novel research areas, will be outlined.

Pathogenesis and genetics

Pathogenic insight into TAK remains poor [7], with direct access to arterial lesions limited to specimens obtained during surgery. Animal models of LVV are confined to: (i) a chimeric model in which sections of temporal artery from patients with GCA are grafted onto an immunodeficient mouse, which is subsequently infused with heterologous human lymphocytes [8], and (ii) IRF-4-binding protein-deficient mice, which develop an IL-17 and IL-21-driven LVV and a rheumatoid-like joint disease [9]. Thus, knowledge of TAK pathogenesis is largely extrapolated from studies in GCA. Arteries from patients with TAK and GCA share many histologic features, leading to the proposition that they may represent a variant of the same disease [10]. However, many important differences in clinical phenotype

exist and it is unknown to what extent pathogenic features described for GCA can be applied to TAK.

Of note, genome-wide association studies have revealed marked genetic differences between GCA and TAK in the *HLA* region, while common susceptibility factors were also revealed within the *IL12B* locus [11]. Genetic data, along with the response to immunosuppressive therapy, support a role for both the adaptive and the innate immune system in TAK (reviewed in [12, 13]). Both Classes I and II *HLA* loci have been associated with TAK (most notably the *HLA-B* locus and the *HLA-B52* allele). Other associated genes include immune-regulatory genes (e.g. *RPS9/LILRB3*, *LILRA3* and *IL38* loci) and inflammatory cytokines (*IL6* and *IL12B* loci) [14–16].

Beyond genetics, recent advances have underlined the importance for health of maintaining arterial integrity and vascular function. Large- and medium-sized arteries are immune-privileged sites, able to blunt immune-inflammatory responses and limit the access of lymphoid cells. Vascular dendritic cells (VDCs) act as gatekeepers. They are present in normal arteries in an inactive state. Studies of GCA implicate VDC activation as an early step in LVV pathogenesis, predisposing to T cell activation, local cytokine release and vascular inflammation [8, 17]. Although the initial pathogenic stimuli are yet to be identified, distinct arterial districts harbour specific populations of VDCs

that exhibit differential expression of activating receptors, including Toll-like receptors [17]. Thus, the local VDC repertoire and specific responses to Toll-like receptor ligands might contribute to the spatial distribution of inflammatory lesions within the arterial tree.

TAK lesions contain macrophages and lymphoid cells ($\alpha\beta$ CD4$^+$ and CD8$^+$ T cells, $\gamma\delta$ T cells, NK cells and B cells). Inflammatory infiltrates lie in close proximity to neoangiogenic *vasa vasora*, which likely represent the portal of access to the arterial wall. The target of the immune response remains elusive, but evidence suggests the local presentation of vasculitogenic antigens, with both priming and maintenance of the immune response occurring in the arterial wall [18]. Indeed, inflamed arteries develop lymphoid follicles and tertiary lymphoid organs, predominantly in the adventitial layer [19]. An important role for Th1 and Th17 responses in the systemic and vascular manifestations of GCA [20] and TAK [21] has been proposed. However, differences in the specific responses seem to exist. Glucocorticoids suppress Th17 cells in GCA, while the Th1 responses typically persist [20]. In contrast, the opposite appears to be true in TAK [21] and further study is required.

In LVV, persistent arterial inflammation predisposes to injury within the vascular stromal compartment, with subsequent remodelling. Studies in GCA suggest that chronic stimulation of myeloid cells (and especially macrophages by lymphocyte-derived cytokines) is a key component [22]. In GCA, multiple changes in arterial wall-infiltrating macrophages have been described, including upregulation of inducible nitric oxide synthase (iNOS) and local release of metalloproteases and growth factors [23–26]. Arteritis in TAK results in neoangiogenesis, leukocytic infiltration with arterial wall oedema, degeneration of smooth muscle and elastic components, fibrosis and hyperplasia of fibroblasts and myofibroblasts. This is accompanied macroscopically by wall thickening and predisposes to arterial stenosis or dilation, which in turn directly impact on clinical features and prognosis (Fig. 2A and B).

Natural history of TAK

Classically TAK is considered triphasic, passing through systemic inflammation and pre-stenotic disease, progressing to stenotic/aneurysmal arterial injury ± pain, and finally to burnt out fibrotic disease (Fig. 1) [27, 28]. However, a systemic inflammatory response is not always detected, and these phases are often difficult to define, with diagnosis typically delayed until the development of phase II and occasionally phase III [27–31].

Large-vessel arteritis confined to the arterial wall and without impact on the arterial lumen is heterogeneous in nature and may include patients with: (i) early TAK; (ii) benign causes of arterial inflammation that do not typically trigger luminal remodelling, which may include aortitis associated with an underlying CTD; and (iii) those in whom significant wall thickening is counterbalanced by compensatory outward positive arterial remodelling that prevents luminal narrowing, analogous to that described for atherosclerosis [32]. Distinguishing between these

groups is of paramount importance, as their prognosis and therapy may differ. Moreover, improved understanding of their pathogenesis may ultimately reveal novel therapeutic targets for the prevention of arterial remodelling.

Currently, a pragmatic clinical approach is used to distinguish disease activity, disease remission and burnt-out disease. Evidence suggests that the duration and course of active disease varies between patients. Kerr and colleagues reported a cohort of 60 patients, 20% of whom exhibited a monophasic self-limiting illness, while 80% had a protracted course requiring long-term therapy [29]. In our combined cohort of 220 patients, 12% presented with inactive burnt-out disease and have not relapsed, despite receiving no immunosuppressive therapy. Turning to those with active disease at presentation, Kerr followed 34/60 patients angiographically, and 88% exhibited disease progression [29]. Our recent prospective longitudinal MR angiography study of unselected patients receiving treatment revealed that 40% of vasculitic lesions remained stable, 37% progressed and 23% improved (median 18 months) [33]. A recent study reported 10-year event-free survival, relapse-free survival and complication-free survival rates approaching 48, 70 and 54% respectively [31]. Likewise, other series have reported no progression in 70 and 77%, respectively [30, 34], while higher levels of relapse have been previously reported elsewhere (reviewed in [35]). Although these differences are likely multifactorial and related in part to a variable definition of vascular progression, they may also reflect greater historic dependence upon CS monotherapy.

Disease progression—recognition of heterogeneity

Progressive arterial injury manifesting as stenosis or dilatation/aneurysm is typically considered inflammatory and treated with enhanced immunosuppression. However, progressive dilatation may also represent a mechanical response to intraluminal blood pressure in previously damaged arterial walls, even in the absence of persistent arterial wall inflammation. Likewise, effective blockade of pivotal pro-inflammatory cytokines with agents targeting TNF-α or IL6 does not always arrest progression of stenotic disease, suggesting other pathways/mechanisms may be involved [36–38]. We propose that, on occasion, in TAK new/progressive stenosis may reflect a stereotyped response to long-standing arterial injury, resulting in non-inflammatory stenosis/remodelling driven predominantly by myofibroblast proliferation [39]. Similarly, resolution of inflammation with fibrosis and luminal contraction may result in progressive arterial narrowing. In both scenarios, any response to increased immunosuppression is likely to be minimal.

Current treatment of TAK

Although outcome data for LVV is relatively poor, it is largely accepted that early diagnosis and treatment can improve disease outcomes. A large study from Japan divided patients into those seen before 1999 and those

FIG. 2 Arterial injury and novel therapeutic targets in TAK

Cartoon illustrating: (**A**) arterial stenosis. This follows invasion of the arterial wall by T cells, B cells and monocyte/macrophages via the *vasa vasorum*, leading to the generation of multinucleate giant cells and fragmentation of the internal elastic lamina. Release of growth factors predisposes to wall oedema, extracellular matrix deposition and the proliferation of myofibroblasts that invade the intima. (**B**) Arterial dilation also follows inflammatory infiltration of the arterial wall by lymphocytes and monocytes. Excessive local release of toxic ROS and MMPs by macrophages is thought to result in degeneration of the tunica media. This predisposes to the death of vascular smooth muscle cells and thinning of the tunica media, disruption of elastin, and weakening and subsequent dilation of the arterial wall. (**C**) The predominant sites of action of current biologic therapies used in TAK and potential novel therapeutic agents and their targets. The diversity of agents and targets raises the prospect of patient stratification and personalized combination therapies for TAK. TAK: Takayasu arteritis; ROS: reactive oxygen species.

after 2000. The latter group were diagnosed earlier, were more likely to have received high-dose combined immunosuppression, and had reduced arterial injury and aortic valve disease [6]. However, the nature of optimal treatment and its duration remain unresolved.

Current treatment options have been covered in detail in recent reviews [36, 40–43] and will be briefly summarized. Although CSs are effective in controlling TAK-associated inflammation and represent the mainstay of therapy, over-

reliance on steroids persists, leading to an unacceptable burden of side-effects. This reflects the relative paucity of controlled clinical trial data [44–46]. Small open-label studies have reported the efficacy of MTX, AZA, MMF, CYC and LEF [47–52]. In those presenting to our centres with active disease, treatment comprises 0.5–1 mg/kg prednisolone plus adjunctive therapy with MTX (maximum dose 15–25 mg/week) or AZA (up to 2 mg/kg/day), with MMF or LEF as alternatives if required. CYC therapy is

largely confined to those with life-threatening disease at presentation or during relapse, including symptomatic cerebral ischaemia or fulminant myocarditis [1, 53].

Biologic therapy in TAK

TAK refractory to conventional immunosuppressive therapy was recently defined [54], and is observed in 15–20% of patients. Although it is widely accepted that TNF-α inhibition [55–59] and IL-6 pathway blockade [60, 61] may control refractory TAK in 60–70% of patients [38, 62], controlled clinical trial data are sparse. This is despite evidence for the potential efficacy of TNF-α and anti-IL-6 antagonists being first reported up to 13 years ago [55, 56, 63]. In the UK, funding for tocilizumab therapy is available for those whose disease is refractory to CSs and at least two immunosuppressants. In many other centres, including those in Italy, a more aggressive approach is adopted, with biologic therapy prescribed after the failure of one immunosuppressive drug [64].

Two trials have demonstrated the efficacy of abatacept and tocilizumab in GCA [65, 66], and two small TAK trials involving these agents have recently been published [67, 68]. The fact that neither trial in TAK met the primary end point likely says more about the challenges of trials in TAK than the efficacy of the drugs. In the abatacept trial, 26 patients were randomized and 18 relapsed. The majority of relapses were symptomatic and, of note, new vascular lesions were only seen in three patients, all of whom were receiving the placebo [67]. In the tocilizumab study, 36 patients with relapsing disease were recruited and randomized into two groups of 18 to receive tocilizumab and CSs or CSs plus placebo. Time to relapse was analysed and a trend towards a positive effect of tocilizumab was reported. Similar trends were reported for disease activity and imaging (CT angiography (CTA) or magnetic resonance angiography (MRA) secondary end-points were used) [68]. Although the time-to-relapse and safety data are encouraging, a longer-term trial with larger numbers and well-defined and quantified vascular outcomes is now required to convincingly show that tocilizumab has a beneficial effect on the vascular outcome of arterial wall inflammation in TAK.

Although biologic therapy is effective [59], relapse is still common, particularly if treatment is withdrawn [42]. Moreover, effective suppression of systemic inflammation and its associated symptoms does not necessarily equate to resolution of arterial wall inflammation [38, 69, 70], and detailed follow-up with arterial imaging is required, initially every 6 months, to exclude progressive arterial disease [37].

The presence of B cells in TAK lesions has led to investigation of the anti-CD20 mAb rituximab in refractory TAK. Results are preliminary and somewhat conflicted. Hoyer and colleagues [71] used flow cytometry to identify three patients with clinically active TAK and an expansion of plasmablasts in peripheral blood. Remission was achieved in all three patients following B cell depletion with rituximab and, similarly, treatment of a further eight refractory patients has suggested rituximab efficacy [72].

In contrast, four out of five patients with refractory TAK exhibited persistent disease activity ± progressive arterial disease despite B cell depletion [73]. Further prospective evaluation of B cell depletion is clearly warranted.

Surgical intervention

Although medical therapy plays the predominant role in TAK, endovascular and open surgical intervention should be considered in specific circumstances [74, 75]. While endovascular approaches are now more commonly applied, the duration of benefit of open surgery tends to be longer [76]. Whenever possible, disease remission should be obtained prior to surgery, with immunosuppression continued during and after surgery [76, 77].

Challenges associated with TAK phenotyping and assessment

Differentiation of TAK from other large vessel vasculitides

The classification of the LVVs, and particularly TAK and GCA, is undergoing further consideration and debate [78–80]. Our ongoing comparative analysis of arterial involvement in TAK and large vessel GCA (LV-GCA) shows intrinsic differences between the two, although the vascular phenotype of some patients with LV-GCA overlaps with that for TAK [81]. The distinction between TAK and GCA is traditionally based on the age at disease onset. Differences in the natural course of disease, histologic features [82], response to immunosuppressive agents, genetics of the HLA region [11] and a stronger association of GCA with intense systemic inflammation further supports this division. However, there are patients who do not fit into the prototypic TAK or GCA classification, or who satisfy criteria for both diseases [82]. Age is not an absolute discriminator, as onset after 40 years of age is reported in 15–20% of patients with TAK [83]. Post-mortem data [84] and, more recently, the increased use of non-invasive imaging has revealed aortic disease and involvement of extra-cephalic branches in up to 60–85% of those with GCA [85–87]. These observations have led to the description of a large-vessel GCA subset (LV-GCA) with a low frequency of cephalic involvement [88, 89], and accordingly novel classification criteria for GCA have been proposed [44]. Likewise, a late-onset TAK classification (>40 years at onset) has been proposed. These patients are phenotypically similar to patients with traditional TAK and more likely to exhibit aortic regurgitation, carotid, subclavian and iliac artery involvement than those classified as GCA [83].

This discussion represents more than an academic debate. In our opinion, effort should be made to reach a global classification for all LVVs. Thus, conditions with potential overlap with TAK and GCA, such as isolated aortitis and giant cell aortitis [90, 91], should be incorporated into a new classification wherever possible. Accurate phenotyping of LVV subtypes is required in order to obtain

homogeneous groups for research studies and clinical trials, and ultimately for optimal clinical care [92].

Analysis of TAK disease activity

Definition and assessment

Although the physician global assessment is a central component of therapeutic decisions in TAK, this is multi-faceted and far from straightforward [93–95]. Assessment includes measurement of systemic inflammation, typically using analysis of acute-phase reactants such as ESR and CRP, alongside review of extra-vascular features such as carotidynia, fever and arthralgia. Additionally, imaging may be used to search for inflammation in the arterial wall and the presence or absence of vascular progression, defined as progressive stenosis or dilatation. However, none of these measures are perfect and often fail to correlate with one another. Indeed, persistent arterial wall inflammation was present in up to 44% of patients undergoing vascular surgery and thought to have inactive disease on the basis of currently available activity measures [29]. Moreover, vascular progression with appearance of new arterial lesions was observed in 61% of patients thought to be inactive [29, 35].

Efforts have been made to address these limitations through the development of the National Institute of Health (NIH) score [29], the Indian Takayasu Activity score (ITAS) and disease-extent index [96] and Takayasu arteritis damage score (TADs) [97], and by the work of the OMERACT working group. NIH score, ITAS (including ITAS-CRP and ITAS-ESR) and TADs, although not fully validated, are readily applied. ITAS and TADs also incorporate cardiovascular weighting when compared with the BVAS and the vasculitis damage index. However, they also have a number of limitations [93]. These are summarized in Table 1, and perhaps foremost among them is the need for the further incorporation of imaging data.

The OMERACT group recently reported on a detailed Delphi exercise involving 92 experts. Important conclusions were reached, including proposal of a preliminary core set of domains in LVV, which include TAK-specific domains [98]. For the assessment of disease activity, development of new indices that incorporate patient-reported outcomes and imaging data is recommended. The OMERACT group have also tested a new damage index. Preliminary results suggest that damage in TAK is predominantly related to the primary disease rather than to treatment-related side-effects [98]. They also identify a critical need, namely for the development of standardized assessment of arterial imaging modalities such as MRI, CT and PET, which is essential for future clinical trials.

Current role of non-invasive imaging

The cardinal role of non-invasive imaging in the management of TAK has been reviewed in detail [99–103]. Response to therapy is typically monitored by MRA or CTA every 6–12 months for the first 2 years. Once disease control has been achieved, the CS dose is gradually weaned to ≤5 mg/day. This is maintained for 6 months, prior to initiating cautious CS withdrawal in those considered clinically inactive, bearing in mind the risk of relapse [29, 35]. Patients are closely monitored and undergo annual MRA. Following 12 months CS-free clinical remission and imaging evidence of stable arterial disease, immunosuppression is gradually weaned. The ultimate aim is treatment withdrawal, typically 5 years from initiation.

The demonstration of arterial wall thickening, multiple arterial lesions and/or luminal abnormalities in the right clinical setting is highly suggestive of TAK. In addition, morphologic assessment aids prediction of vascular complications and prognosis, the evaluation of arterial disease progression and the planning of interventional procedures. The different imaging modalities are conceptually divided into those that analyse arterial morphology (luminal changes and/or wall thickening) and those techniques that functionally characterize vasculitic lesions (Table 2). Unenhanced colour Doppler US, digital subtraction angiography and MRI-based angiographic studies belong to the former, with PET and PET/CT in the latter category (Fig. 1). Contrast-enhanced US (CEUS), CTA and MRI can assess both vascular morphology and identify arterial wall enhancement.

Arterial wall imaging may reveal the presence of oedema or contrast enhancement. More acute changes, including the presence of oedema, may be reversible with treatment [104–106]. However, the link between arterial wall oedema or enhancement and clinical measures of disease activity or subsequent disease progression with luminal encroachment has not been conclusively demonstrated [107, 108].

2-[^{18}F]-fluoro-2-deoxy-D-glucose PET (^{18}F-FDG-PET) co-registered with CT is widely applied in TAK [103]. Its principal role is in diagnosis, where the identification of enhanced metabolic activity may improve diagnostic accuracy and influence therapeutic decisions [109]. However, during follow-up the precise role of ^{18}F-FDG-PET is less clear [110, 111]. Cumulative radiation exposure is a concern, and the accuracy of ^{18}F-FDG-PET/CT for the detection of low-grade relapsing or partially treated arteritis is limited and study data variable [112–115]. On occasion, increased arterial FDG uptake may provide additional information. However, in the absence of correlative biopsy data, interpretation of low-level arterial FDG uptake is complex as it may reflect a variety of processes, including arterial wall inflammation, non-inflammatory myofibroblast proliferation, vascular remodelling, active fibrosis or atherogenesis.

Two recent studies have considered further the role of ^{18}F-FDG-PET/CT in identification of disease activity and prediction of progression. The first conducted a detailed analysis of arterial wall lesions using both ^{18}F-FDG-PET/CT and MRI. The data revealed no correlation between arterial wall FDG uptake and either systemic inflammation or disease activity measured using the NIH score [110]. However, the thickness of FDG-avid arterial lesions correlated with their maximum standardized uptake values (SUV$_{max}$). The findings suggest that ^{18}F-FDG-PET/CT may be useful for the identification of active local arterial wall inflammation and/or remodelling in those with

Table 1 Assessment of current disease activity and damage indices for Takayasu arteritis

Tool	Assessment	Pros	Cons
NIH criteria [29]	Disease activity	Multi-item score, assessing different disease features. Practical, easy to apply. Includes imaging data.	Relies on new/worsening disease features: inaccurate for first assessment or infrequent visits. Cut-off for individual items undefined. Inappropriate for persistent active disease. Includes only on angiographic data. Not validated.
ITAS ITAS-CRP ITAS-ESR [92]	Disease activity	Multi-item score, assessing different disease features. Allows grading of disease activity. Distinguishes features of active and inactive vasculitis. Allows grading according to the number of worsening vessels. Cardiovascular weighting.	Relies on new/worsening disease features: inaccurate for the first assessment or infrequent visits. Inappropriate for persistent active disease. Imaging data not included. Limited validation (to PGA and NIH). Dependence on the location of vascular lesions; the same lesions can affect multiple items (e.g. a new subclavian artery occlusion leading to pulse inequalities, claudication and loss of more than one pulse).
TADS [93]	Disease damage	Multi-item score, assessing different disease features. Allows grading of severity using a multi-item score. Weights cardiovascular damage. Accounts for vascular procedures.	Cannot identify damage present for <6 months. Relative underscoring of the splanchnic arteries. Limited inclusion of imaging data. Lack of validation, especially for longitudinal analysis.
DEI-Tak [92]	Disease extent	Multi-item score, assessing different disease features. Reflects both features of activity and damage.	Time-consuming. Relevance for assessment of disease extent remains to be confirmed. The same arterial lesions can affect multiple items (e.g. a new subclavian artery occlusion leading to pulse inequalities, claudication and loss of more than one pulse). Does not take into account imaging or laboratory data. Limited validation (to PGA and NIH).

NIH: National Institute of Health; ITAS: Indian Takayasu Activity Score; TADS: Takayasu arteritis Damage Score; DEI-Tak: Disease Extent Index-Takayasu; PGA: Physician Global Assessment.

TABLE 2 Conceptual classification of imaging techniques for TAK assessment

Morphological depiction of arteries		Functional characterization of the arterial wall
Arterial lumen	**Arterial wall**	
CDUS	CDUS	CDUS (halo sign), CE-US
CT-angiography	CT-angiography	CE-CT
MR-angiography	Vessel wall MRI	T2-weighted MRI sequences, CE-MRI
Digital subtraction angiography		PET, PET/CT and PET/MRI

CE-CT/MRI: contrast enhanced-CT/MRI; CE-US: contrast-enhanced ultrasonography; CDUS: colour Doppler ultrasonography.

clinically active disease, so revealing a subset potentially at risk of disease progression. The second study generated rare prospective data regarding the use of ^{18}F-FDG-PET/CT in patients with TAK and in a comparator group with diseases mimicking LVV [116]. A qualitative score was developed (PETVAS), based on global arterial FDG uptake. ^{18}F-FDG-PET/CT proved most sensitive and specific in those with clinically active disease. Interpretation of the uptake in 58% of positive scans of those with clinically inactive disease proved more challenging. However, preliminary evidence suggests that these patients were more at risk of disease relapse, and similarly a PETVAS cut-off of ⩾20 also seemed to be a useful predictor [116].

Current thinking suggests that luminal assessment and arterial wall analyses, either morphologically or functionally, are complementary. The former provides the most clinically relevant data concerning disease extent, disturbances to blood flow and the risk of end-organ ischaemia. The latter may provide insight into pathogenic events occurring early in the arterial wall and facilitate diagnosis of pre-stenotic/pre-angiographic disease. Ultimately, it may also aid assessment of disease activity and predict vascular remodelling. However, further studies are needed to verify whether characterization of arterial wall thickness and enhancement can predict vascular outcomes [103].

Reflecting this uncertainty and in light of resource restrictions, a pragmatic approach is often adopted in the clinic, so that MRI studies during follow-up are often limited to assessment of the arterial lumen. This approach requires a much shorter MRI acquisition time than detailed assessment of changes in the arterial wall. Furthermore, we have shown that monitoring in this way with MRI allows accurate assessment of disease extent and phenotype and long-term monitoring of disease evolution [33].

Recent exciting discoveries, future prospects and challenges

Novel plasma biomarker discovery

The multiple unresolved issues in the management of TAK highlight the need for novel biomarkers to aid clinical decision-making. Identification of these is no small task. Biomarkers are needed for the identification of LVV subsets, for accurate assessment of disease activity, as predictors of response to specific therapies or risk of future relapses. Additional biomarkers are required for

distinguishing inflammatory and non-inflammatory remodelling. Recent research has focused on disease activity biomarkers [117]. However, advances have been minimal, with the new biomarkers variably associated with acute-phase reactants or with activity indices. In the last year, soluble HLA-E, serum amyloid-A, IL-6 and soluble IL6-receptor have been associated with current activity indices [118–120]. Previous studies have explored the relationship between plasma biomarkers, arterial wall inflammation and vascular progression [121, 122]. Pentraxin-3 (PTX3) is directly released at sites of inflammation and exhibits multiple functions, including the modulation of tissue repair/remodelling. PTX-3 levels were shown to correlate with vascular progression but not with systemic inflammation as assessed by CRP and ESR [122]. A subsequent study also reported higher PTX-3 in patients with TAK than in healthy controls, although there was no association with disease activity [123]. Thus, PTX-3 may represent a marker of increased risk of progressive arterial injury, and further research is needed to define its potential clinical utility in TAK management.

New approaches to imaging

Imaging biomarkers offer significant potential because they allow serial non-invasive assessments. Although it remains to be determined how closely imaging data reflects arterial wall inflammation and the subsequent risk of luminal remodelling, an optimal clinical assessment based upon imaging biomarkers reflecting local pathogenic events, combined with clinical and plasma biomarker data is a valid aspiration. Novel and predominantly research-based imaging techniques are improving identification of pathology associated with tissue inflammation. When compared with colour Doppler US, a study of both TAK and GCA reported that microbubble CEUS optimizes assessment of arterial wall lesions and detects neovessel development [124]. Further evidence suggests that CEUS is able to quantify disease activity and monitor treatment responses in TAK-associated carotid arteritis [125, 126].

In another small study of 12 patients with TAK or GCA, conventional ^{18}F-FDG-PET-CT was compared with ^{18}F-FDG-PET-MRI. The latter compared favourably with ^{18}F-FDG-PET-CT, and in addition demonstrated enhanced soft-tissue resolution and proved optimal for determining disease extent [127]. As a glucose analogue, FDG is taken up by any metabolically active tissue and

hence lacks specificity for inflammatory cells. Thus, additional PET ligands are being sought for the detection of different phases of arterial disease in TAK. [^{11}C]-PK11195 binds the translocator protein (TSPO) which is highly expressed by activated monocytes and macrophages. [^{11}C]-PK11195-PET demonstrated arterial wall uptake in all six symptomatic LVV (GCA and TAK) patients and in none of the asymptomatic controls [128]. Second-generation TSPO ligands circumvent many of the technical issues associated with [^{11}C]-PK11195 [129]. However, ligand binding is significantly reduced by a common TSPO polymorphism (rs6971), with a minor allele frequency of up to 30%. Therefore genotyping is required or alternative ligands for TAK need to be identified that are not affected by rs6971 [130]. The latter might include ligands shown to bind activated macrophages in atherosclerotic plaque, such as those targeting the integrin $\alpha_V\beta_3$ [131] and somatostatin receptor subtype-2 [132].

PET imaging using novel and more specific ligands, co-registered with images derived from the more powerful and sensitive 7 T MRI scanners [133], may eventually offer accurate assessment of both disease activity and arterial injury. PET-MRI may prove to be the approach that overcomes the challenge of detecting persistent low-grade arterial wall inflammation or early relapse.

Novel approaches to therapy

The paucity of clinical trial data in TAK has a direct impact on patients and leaves funding agencies reluctant to endorse reimbursement for biologic therapies. Although further controlled clinical trials are urgently needed, the design and conduct of clinical trials in TAK is challenging, and recruitment of sufficient numbers with active disease within a specific time-frame necessitates multicentre trials [45]. Moreover, TAK disease activity indices, including ITAS and the NIH score, require further optimization and as yet there are no validated biomarkers for distinguishing active arteritis and arterial damage [117].

Clinical trials in LVV have typically focused upon end-points measuring systemic inflammation as an index of disease activity, which may not be a true measure of arterial wall inflammation or the likelihood or presence of arterial disease progression [95]. Arterial, injury and remodelling predispose to stenoses and aneurysms and are directly linked to prognosis in TAK (Fig. 2A and B). Thus, prevention of arterial disease progression is the fundamental therapeutic goal. Incorporation of imaging end-points of disease activity (^{18}F-FDG-PET) or arterial involvement (MRS/CTA) into clinical trials is desirable. However, these modalities remain very expensive and not universally available. Furthermore, standardized methods for quantifying imaging data also remain to be developed. We and others are investigating novel approaches for image analysis [33, 81, 134]. Similarly, the OMERACT working group is working towards development of a core set of outcomes for LVV, incorporating imaging data [93, 98].

The plethora of biologic agents, their emerging biosimilars and oral targeted disease-modifying therapies aimed at inflammatory arthritis also offer promise for LVV [135] (Fig. 2C). Recent advances in our understanding of disease pathogenesis will aid selection of the most appropriate agents [21, 136–138]. Similarly, identification of novel biomarkers that can distinguish active arterial wall inflammation from non-inflammatory progressive vascular remodelling is essential. While targeting IL-6, TNF-α, IL-12/23 or IL-17 might be optimal for targeting active arterial inflammation, anti-proliferative agents such as rapamycin or calcineurin inhibitors might be required for the latter. Clinical trials of all these agents are required. The common susceptibility factors for GCA and TAK at the *IL12B* locus, and early clinical data indicating that the IL-12/23 antagonist ustekinumab may be effective in refractory GCA [139, 140], suggests that this agent is worthy of trial in TAK [141]. Similarly, the novel Janus kinase (JAK) inhibitors tofacitinib, an inhibitor of JAK1 and 3, and baricitinib (JAK1/2) offer exciting possibilities in LVV. Numerous upstream pro-inflammatory cytokines and types I and II IFNs signal via members of the JAK family. Tofacitinib and baricitinib are approved for use in RA and are being investigated in a variety of other chronic inflammatory diseases [142].

Important and often overlooked aspects of treatment in TAK are those in which the patient can take control. These include cardiovascular risk factor management, such as maintaining a healthy diet, cessation of smoking and regular exercise. For example, in those with limb claudicant symptoms, regular exercise encourages the development of a collateral circulation and offers symptom relief. A recent report shows that 12 weeks of aerobic exercise reduces circulating TNF-α and increases the pro-angiogenic cytokines VEGF and PDGF-AA, leading to enhanced muscle strength and function [143]. Although no change in quality of life was seen in this short study, it sets an important precedent regarding the safety of exercise and the biologic plausibility of its effects.

Conclusion

Recent evidence suggests that increased recognition of LVV, rapid development of non-invasive imaging, the early use of combined immunosuppression and increased availability of biologic therapy may be improving outcomes in TAK. Future challenges include the need to reduce the burden of steroid toxicity, to improve understanding of disease pathogenesis, and to identify novel biomarkers for each phase of the disease and defined end-points for future clinical trials. The ultimate aim in TAK is to find a therapeutic combination capable of controlling all aspects of disease. These include its effects in the macro- and microcirculation and its propensity to induce pulmonary arterial hypertension. The most effective combination therapy is likely to reflect the nature of TAK, a condition at the crossroads between immune-mediated rheumatic disease and cardiovascular medicine.

Acknowledgements

References

1 Mason JC. Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol 2010;6:406–15.

2 Mathew AJ, Goel R, Kumar S, Danda D. Childhood-onset Takayasu arteritis: an update. Int J Rheum Dis 2016;19:116–26.

3 Chung JW, Kim HC, Choi YH *et al*. Patterns of aortic involvement in Takayasu arteritis and its clinical implications: evaluation with spiral computed tomography angiography. J Vasc Surg 2007;45:906–14.

4 Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 1996;54 (Suppl):S155–63.

5 Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation 1994;90:1855–60.

6 Ohigashi H, Haraguchi G, Konishi M *et al*. Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 2012;76:1004–11.

7 Tombetti E, Mason JC. Pathophysiology of vasculitis. In: Krams R, Back M, eds. The ESC textbook of vascular biology, 1st edn . Oxford: Oxford University Press, 2017: 253–72.

8 Ma-Krupa W, Jeon M-S, Spoerl S *et al*. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004;199:173–83.

9 Chen Q, Yang W, Gupta S *et al*. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008;29:899–911.

10 Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine 2009;88:221–6.

11 Carmona FD, Coit P, Saruhan-Direskeneli G *et al*. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 2017;7:43953.

12 Renauer P, Sawalha AH. The genetics of Takayasu arteritis. Presse Med 2017;46:e179–87.

13 Terao C. Revisited HLA and non-HLA genetics of Takayasu arteritis—where are we? J Hum Genet 2016;61:27–32.

14 Renauer PA, Saruhan-Direskeneli G, Coit P *et al*. Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu arteritis in a genome-wide association study. Arthritis Rheumatol 2015;67:1361–8.

15 Saruhan-Direskeneli G, Hughes T, Aksu K *et al*. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J Hum Genet 2013;93:298–305.

16 Terao C, Yoshifuji H, Kimura A *et al*. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 2013;93:289–97.

17 Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008;118:1276–84.

18 Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 2011;11:61–7.

19 Clement M, Galy A, Bruneval P *et al*. Tertiary lymphoid organs in Takayasu arteritis. Front Immunol 2016;7:158.

20 Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121:906–15.

21 Saadoun D, Garrido M, Comarmond C *et al*. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 2015;67:1353–60.

22 Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 2013;9:731–40.

23 Kaiser M, Weyand CM, Björnsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998;41:623–33.

24 Nikkari ST, Höyhtyä M, Isola J, Nikkari T. Macrophages contain 92-kd gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996;149:1427–33.

25 Wagner AD, Goronzy JJ, Weyand CM. Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. J Clin Invest 1994;94:1134–40.

26 Weyand CM, Wagner AD, Björnsson J, Goronzy JJ. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;98:1642–9.

27 Hall S, Barr W, Lie JT *et al*. Takayasu arteritis. A study of 32 North American patients. Medicine 1985;64:89–99.

28 Lupi-Herrera E, Sánchez-Torres G, Marcushamer J *et al*. Takayasu's arteritis. Clinical study of 107 cases. Am Heart J 1977;93:94–103.

29 Kerr GS, Hallahan CW, Giordano J *et al*. Takayasu arteritis. Ann Intern Med 1994;120:919–29.

30 Mwipatayi BP, Jeffery PC, Beningfield SJ *et al*. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 2005;75:110–7.

31 Comarmond C, Biard L, Lambert M *et al*. Long-term outcomes and prognostic factors of complications in Takayasu's arteritis: a multicenter study of 318 patients. Circulation 2017;136:1114–22.

32 Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human

atherosclerotic coronary arteries. N Engl J Med 1987;316:1371–5.

33 Tombetti E, Zia A, Gopalan D et al. A novel MRI-based longitudinal scoring system for arterial involvement in large-vessel vasculitis. Ann Rheum Dis 2015;74:518.

34 Mandalam KR, Subramanyan R, Joseph S et al. Natural history of aortoarteritis: an angiographic study in 26 survivors. Clin Radiol 1994;49:38–44.

35 Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000–9.

36 Tombetti E, Di Chio MC, Sartorelli S et al. Anti-cytokine treatment for Takayasu arteritis: state of the art. Intractable Rare Dis Res 2014;3:29–33.

37 Youngstein T, Mason JC. Interleukin 6 targeting in refractory Takayasu arteritis: serial noninvasive imaging is mandatory to monitor efficacy. J Rheumatol 2013;40:1941–4.

38 Youngstein T, Peters JE, Hamdulay SS et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis. Clin Exp Rheumatol 2014;32:S11–8.

39 Nicolosi PA, Tombetti E, Maugeri N et al. Vascular remodelling and mesenchymal transition in systemic sclerosis. Stem Cells Int 2016;2016:4636859.

40 Keser G, Aksu K. What is new in management of Takayasu arteritis? Presse Med 2017;46:e229–35.

41 Misra DP, Sharma A, Kadhiravan T, Negi VS. A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev 2017;16:179–91.

42 Muratore F, Pipitone N, Salvarani C. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. Expert Rev Clin Immunol 2017;13:1–16.

43 Kermani TA, Dasgupta B. Current and emerging therapies in large-vessel vasculitis. Rheumatology 2018;57:1513–24.

44 Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 2017;56:506–15.

45 Tarzi RM, Mason JC, Pusey CD. Issues in trial design for ANCA-associated and large-vessel vasculitis. Nat Rev Rheumatol 2014;10:502–10.

46 Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318–23.

47 Hoffman GS, Leavitt RY, Kerr GS et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578–82.

48 Valsakumar AK, Valappil UC, Jorapur V et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 2003;30:1793–8.

49 Shelhamer JH, Volkman DJ, Parrillo JE et al. Takayasu's arteritis and its therapy. Ann Intern Med 1985;103:121–6.

50 de Souza AW, da Silva MD, Machado LS et al. Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 2012;41:227–30.

51 Goel R, Danda D, Mathew J, Edwin N. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 2010;29:329–32.

52 Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 2007;26:1871–5.

53 Bechman K, Gopalan D, Nihoyannopoulos P, Mason JC. A cohort study reveals myocarditis to be a rare and life-threatening presentation of large vessel vasculitis. Semin Arthritis Rheum 2017;47:241–6.

54 Sahin Z, Bicakcigil M, Aksu K et al. Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Res Ther 2012;14:R27.

55 Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296–304.

56 Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567–9.

57 Quartuccio L, Schiavon F, Zuliani F et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 2012;30:922–8.

58 Schmidt J, Kermani TA, Bacani AK et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res 2012;64:1079–83.

59 Gudbrandsson B, Molberg Ø, Palm Ø. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study. Arthritis Res Ther 2017;19:99.

60 Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. Int J Rheum Dis 2013;16:754–61.

61 Tombetti E, Franchini S, Papa M, Sabbadini M, Baldissera E. Treatment of refractory Takayasu arteritis with tocilizumab: seven Italian patents from a single referral center. J Rheumatol 2013;40:2047–51.

62 Mekinian A, Comarmond C, Resche-Rigon M et al. Efficacy of biological-targeted treatments in Takayasu Arteritis: multicenter, retrospective study of 49 patients. Circulation 2015;132:1693–700.

63 Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008;58:1197–2000.

64 Tombetti E, Manfredi A, Sabbadini MG, Baldissera E. Management options for Takayasu arteritis. Expert Opin Orphan Drugs 2013;1:685–93.

65 Langford CA, Cuthbertson D, Ytterberg SR et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol 2017;69:837–45.

66 Stone JH, Tuckwell K, Dimonaco S et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28.

67 Langford CA, Cuthbertson D, Ytterberg SR et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 2017;69:846–53.

68 Nakaoka Y, Isobe M, Takei S et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018;77:348–54.

69 Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;30:S98–100.

70 Xenitidis T, Horger M, Zeh G, Kanz L, Henes JC. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology 2013;52:1729–31.

71 Hoyer BF, Mumtaz IM, Loddenkemper K et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012;71:75–9.

72 Nakagomi D, Kronbichler A, Witte T, Mohammad AJ, Jayne D. Efficacy of rituximab in Takayasu arteritis: a case series. Rheumatology 2017;56 (Suppl 3):iii51–2.

73 Pazzola G, Muratore F, Boiardi L et al. Rituximab in patients with Takayasu Arteritis: a single center experience on five patients. Arthritis Rheumatol 2016;68 (Suppl 10):907.

74 Mason JC. Takayasu arteritis: surgical interventions. Curr Opin Rheumatol 2015;27:45–52.

75 Ogino H, Matsuda H, Minatoya K et al. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 2008;118:2738–47.

76 Perera AH, Youngstein T, Gibbs RG et al. Optimizing the outcome of vascular intervention for Takayasu arteritis. Br J Surg 2014;101:43–50.

77 Saadoun D, Lambert M, Mirault T et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation 2012;125:813–9.

78 Furuta S, Cousins C, Chaudhry A, Jayne D. Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity? J Rheumatol 2015;42:300–8.

79 Grayson PC, Maksimowicz-McKinnon K, Clark TM et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 2012;71:1329–34.

80 Kermani TA, Crowson CS, Muratore F et al. Extra-cranial giant cell arteritis and Takayasu arteritis: how similar are they? Semin Arthritis Rheum 2015;44:724–8.

81 Tombetti E, Ambrosi A, Godi C et al. Understanding the heterogeneity of large-vessel vasculitides. Ann Rheum Dis 2017;76 (Suppl 2):316–7.

82 Koster MJ, Warrington KJ. Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? Presse Med 2017;46:e205–13.

83 Yoshida M, Watanabe R, Ishii T et al. Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int J Rheum Dis 2016;19:87–94.

84 Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3532–7.

85 Blockmans D, de Ceuninck L, Vanderschueren S et al. Repetitive ^{18}F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131–7.

86 Aschwanden M, Kesten F, Stern M et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2×11 arterial regions. Ann Rheum Dis 2010;69:1356–9.

87 Prieto-González S, Arguis P, García-Martínez A et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012;71:1170–6.

88 de Boysson H, Liozon E, Lambert M et al. ^{18}F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: a multicenter cohort of 130 patients. Medicine 2016;95:e3851.

89 Muratore F, Kermani TA, Crowson CS et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology 2015;54:463–70.

90 Ryan C, Barbour A, Burke L, Sheppard MN. Non-infectious aortitis of the ascending aorta: a histological and clinical correlation of 71 cases including overlap with medial degeneration and atheroma—a challenge for the pathologist. J Clin Pathol 2015;68:898–904.

91 Svensson LG, Arafat A, Roselli EE et al. Inflammatory disease of the aorta: patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis. J Thorac Cardiovasc Surg 2015;149:S170–5.

92 Tombetti E, Rovere-Querini P, Manfredi AA. Clinical trials in rheumatology. Does one size fit all? Rheumatology 2016;56:675–6.

93 Direskeneli H. Clinical assessment in Takayasu's arteritis: major challenges and controversies. Clin Exp Rheumatol 2017;35 (Suppl 103):189–93.

94 Nakagomi D, Jayne D. Outcome assessment in Takayasu arteritis. Rheumatology 2016;55:1159–71.

95 Aydin SZ, Merkel PA, Direskeneli H. Outcome measures for Takayasu's arteritis. Curr Opin Rheumatol 2015;27:32–7.

96 Misra R, Danda D, Rajappa SM et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology 2013;52:1795–801.

97 Rajappa SM. Outcome of vascular interventions in Takayasu Arteritis using the Takayasu Arteritis Damage Score [abstract]. Arthritis Rheum 2011;63 (Suppl 10):1504.

98 Sreih AG, Alibaz-Oner F, Kermani TA et al. Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016. J Rheumatol 2017;44:1933–7.

99 Ammirati E, Moroni F, Pedrotti P et al. Non-invasive imaging of vascular inflammation. Front Immunol 2014;5:399.

100 Hartlage GR, Palios J, Barron BJ et al. Multimodality imaging of aortitis. JACC Cardiovasc Imaging 2014;7:605–19.

101 Prieto-González S, Arguis P, Cid MC. Imaging in systemic vasculitis. Curr Opin Rheumatol 2015;27:53–62.

102 Prieto-González S, Espígol-Frigolé G, Garcia-Martinez A et al. The expanding role of imaging in systemic vasculitis. Rheum Dis Clin North Am 2016;42:733–51.

103 Tombetti E, Mason JC. Application of imaging techniques for Takayasu arteritis. Presse Med 2017;46:e215–23.

104 Fukudome Y, Abe I, Onaka U et al. Regression of carotid wall thickening after corticosteroid therapy in Takayasu's arteritis evaluated by B-mode ultrasonography: report of 2 cases. J Rheumatol 1998;25:2029–32.

105 Kato Y, Terashima M, Ohigashi H et al. Vessel wall inflammation of Takayasu Arteritis detected by contrast-enhanced magnetic resonance imaging: association with disease distribution and activity. PLoS One 2015;10:e0145855.

106 Papa M, De Cobelli F, Baldissera E et al. Takayasu arteritis: intravascular contrast medium for MR angiography in the evaluation of disease activity. Am J Roentgenol 2012;198:W279–84.

107 Tso E, Flamm SD, White RD et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002;46:1634–42.

108 Eshet Y, Pauzner R, Goitein O et al. The limited role of MRI in long-term follow-up of patients with Takayasu's arteritis. Autoimmun Rev 2011;11:132–6.

109 Fuchs M, Briel M, Daikeler T et al. The impact of ^{18}F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012;39:344–53.

110 Incerti E, Tombetti E, Fallanca F et al. ^{18}F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis. Eur J Nucl Med Mol Imaging 2017;44:1109–18.

111 Youngstein T, Tombetti E, Mukherjee J et al. FDG uptake by prosthetic arterial grafts in large vessel vasculitis is not specific for active disease. JACC Cardiovasc Imaging 2017;10:1042–52.

112 Lee KH, Cho A, Choi YJ et al. The role of ^{18}F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum 2012;64:866–75.

113 Tezuka D, Haraguchi G, Ishihara T et al. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. JACC Cardiovasc Imaging 2012;5:422–9.

114 Alibaz-Oner F, Dede F, Ones T, Turoglu HT, Direskeneli H. Patients with Takayasu's arteritis having persistent acute-phase response usually have an increased major vessel uptake by 18F-FDG-PET/CT. Mod Rheumatol 2015;25:752–5.

115 Arnaud L, Haroche J, Malek Z et al. Is ^{18}F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 2009;60:1193–200.

116 Grayson PC, Alehashemi S, Bagheri AA et al. ^{18}F-fluorodeoxyglucose–positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol 2017 (in press) doi: 10.1002/art.40379.

117 Tombetti E, Mason JC. Large vessel vasculitis: the search for response biomarkers. Expert Rev Clin Immunol 2016;12:1011–3.

118 Goel R, Kabeerdoss J, Mohan H et al. Soluble-HLA-E: a follow up biomarker in Takayasu arteritis, independent of HLA-E genotype. Int J Rheum Dis 2018;21:532–40.

119 Nair AM, Goel R, Hindhumati M et al. Serum amyloid A as a marker of disease activity and treatment response in Takayasu arteritis. Rheumatol Int 2017;37:1643–9.

120 Pulsatelli L, Boiardi L, Assirelli E et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol 2017;35 (Suppl 103):102–10.

121 Tombetti E, Colombo B, Di Chio MC et al. Chromogranin-A production and fragmentation in patients with Takayasu arteritis. Arthritis Res Ther 2016;18:187.

122 Tombetti E, Di Chio M, Sartorelli S et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther 2014;16:479.

123 Alibaz-Oner F, Aksu K, Yentur SP et al. Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Clin Exp Rheumatol 2016;34:73–6.

124 Schinkel AF, van den Oord SC, van der Steen AF, van Laar JA, Sijbrands EJ. Utility of contrast-enhanced ultrasound for the assessment of the carotid artery wall in patients with Takayasu or giant cell arteritis. Eur Heart J Cardiovasc Imaging 2014;15:541–6.

125 Giordana P, Baque-Juston MC, Jeandel PY et al. Contrast-enhanced ultrasound of carotid artery wall in Takayasu disease: first evidence of application in diagnosis and monitoring of response to treatment. Circulation 2011;124:245–7.

126 Magnoni M, Dagna L, Coli S et al. Assessment of Takayasu arteritis activity by carotid contrast-enhanced ultrasound. Circ Cardiovasc Imaging 2011;4:e1–2.

127 Einspieler I, Thurmel K, Pyka T et al. Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging 2015;42:1012–24.

128 Pugliese F, Gaemperli O, Kinderlerer AR et al. Imaging of vascular inflammation with [^{11}C]-PK11195 and PET/CT angiography. J Am Coll Cardiol 2010;56:33–9.

129 Narayan N, Owen DR, Taylor PC. Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology 2017;56:1837–46.

130 Owen DR, Yeo AJ, Gunn RN et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012;32:1–5.

131 Laitinen I, Saraste A, Weidl E et al. Evaluation of $\alpha_v\beta_3$ integrin-targeted positron emission tomography tracer ^{18}F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging 2009;2:331–8.

132 Tarkin JM, Joshi FR, Evans NR et al. Detection of Atherosclerotic Inflammation by ^{68}Ga-DOTATATE PET compared to [^{18}F]FDG PET imaging. J Am Coll Cardiol 2017;69:1774–91.

133 Goll C, Thormann M, Hofmüller W *et al*. Feasibility study: 7 T MRI in giant cell arteritis. Graefes Arch Clin Exp Ophthalmol 2016;254:1111–6.

134 Nakagomi D, Cousins C, Sznajd J *et al*. Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS). Clin Exp Rheumatol 2017;35 (Suppl 103):139–45.

135 Samson M, Espigol-Frigole G, Terrades-Garcia N *et al*. Biological treatments in giant cell arteritis & Takayasu arteritis. Eur J Intern Med 2017; doi:10.1016/j.ejim.2017.11.003.

136 Miyabe C, Miyabe Y, Strle K *et al*. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 2017;76:898–905.

137 Wen Z, Shimojima Y, Shirai T *et al*. NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs. J Clin Invest 2016;126:1953–67.

138 Nadkarni S, Dalli J, Hollywood J *et al*. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res 2014;114:242–8.

139 Conway R, O'Neill L, O'Flynn E *et al*. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016;75:1578–9.

140 Samson M, Ghesquière T, Berthier S, Bonnotte B. Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis. Ann Rheum Dis 2018;77:e6.

141 Terao C, Yoshifuji H, Nakajima T *et al*. Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol 2016;45:80–2.

142 Gadina M, Gazaniga N, Vian L, Furumoto Y. Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases. J Autoimmun 2017;85:20–31.

143 Oliveira DS, Shinjo SK, Silva MG *et al*. Exercise in Takayasu Arteritis: effects on inflammatory and angiogenic factors and disease-related symptoms. Arthritis Care Res 2017;69:892–902.